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Abstract
Background: In the past decade, migraine research has identified novel drug targets. In this review, we discuss
recent data on emerging anti-migraine therapies.
Main body: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies
for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and
ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not
effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific
prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer
convenient treatment regimens of 4- or 12-week intervals.
Conclusion: Collectively, novel migraine therapies represent a major progress in migraine treatment and will
undoubtedly transform headache medicine.
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Introduction
The last ten years have witnessed remarkable discoveries
in migraine research [1, 2] and migraine therapy is cur-
rently undergoing tremendous development. Based on
these discoveries, novel targeted acute and preventive
therapies have emerged including ditans (5-HT1F recep-
tor agonists), gepants (calcitonin gene-related peptide
(CGRP) receptor antagonists) and anti-CGRP monoclonal
antibodies (mAbs). Novel therapies signify a paradigm
shift in the migraine management and bring new hope to
patients and clinicians. This review provides an overview
of new drugs for both acute and prophylactic treatments
of migraine, covering studies on clinical evidence, toler-
ability, and the different stages of clinical development.
Novel acute treatment targets
5-HT1F receptor agonists (ditans)
Triptans are 5-HT1B/1D receptor agonists with some affin-
ity for the 5-HT1F receptor subtype and commonly used
as acute anti-migraine drugs [3]. The rationale for the de-
velopment of triptans was based on the vasoconstricting
effect via the 5-HT1B receptor subtype [4]. However, some
studies have questioned the role of vasoconstriction in
anti-migraine effect of triptans [5]. Therefore, drug
pharmacological studies have focused on the 5-HT1D [6,
7] and 5-HT1F receptors that do not a vasoconstrictive ef-
fect [8–10]. These receptors are interesting drug targets as
triptans are contraindicated in migraine patients with
coexisting cardiovascular disorders [11–15]. The 5-HT1D
subtype is expressed in the human trigeminal ganglion
and co-localize with CGRP [6]. A phase II trial investigated
the efficacy of 5-HT1D agonists, but did not meet its primary
endpoints and its development was discontinued [7]. There-
fore, drug discovery programs shifted focus to the 5-HT1F
subtype. This receptor subtype is located in the trigeminal
ganglion, the trigeminal nucleus caudalis and cephalic blood
vessels, but importantly, activation of this receptor do not
constrict blood vessels [8–10]. Interestingly, sumatriptan
and naratriptan binds to the 5-HT1F receptor with a high af-
finity [9]. Based on these studies, 5-HT1F agonists have been
developed and categorized as a new drug class: ditans. Stud-
ies of ditans in preclinical models suggested an involvement
in the modulation of dural neurogenic inflammation and
the trigeminovascular system, establishing the 5-HT1F re-
ceptor as a potential target for migraine treatment [16].
Three compounds exist, LY 344864, LY334370 and
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lasmiditan, but only the last two have been tested in
humans. While LY334370 demonstrated a clinical effect in a
proof of concept study [17], the development of LY334370
was terminated due to hepatic toxicity in animal models
[18]. Accordingly, only lasmiditan is still undergoing clinical
trials (Table 1).
Lasmiditan is a 5-HT1F receptor agonist [19] which is ad-
ministrated orally in 50–200mg doses and it has a tmax of
1.5–2.5 h [20]. Of the three phase III clinical trials (SAM-
URAI, NCT02439320 [21]; SPARTAN, NCT02605174 [22];
GLADIATOR, NCT02565186 [23]), to date only one
(SAMURAI [24]) has been published [24]. Preliminary data
from press releases for the remaining two are presented as
following [25, 26] (Fig. 1).
In SAMURAI, 2231 patients were randomized to oral
intake of lasmiditan 100mg, 200mg or placebo [24]. This
trial excluded patients with known coronary artery dis-
ease, clinically significant arrhythmia or uncontrolled
hypertension. The percentage of patients with 2-h pain
freedom was 28.2% (vs. placebo, p < 0.001) in the 100mg
group, 32.2% (vs. placebo, p < 0.001) in the 200mg group
and 15.3% in the placebo group [27]. The percentage of
patients with freedom from most bothersome symptom at
2-h was 40.9% (vs. placebo, p < 0.001) in the 100mg
group, 40.7% (vs. placebo, p < 0.001) in the 200mg group
compared to 29.5% in the placebo group. The most com-
mon adverse events were dizziness and paresthesia and
both mild to moderate intensity. Dizziness occurred in
11.9% of the 100mg group and 15.4% of the 200mg
group. Paresthesia occurred in 5.7% of the 100mg group
and 7.6% of the 200mg group compared to 3.1% and 2.1%
in the placebo group. No serious adverse events occurred.
In SPARTAN, patients were randomized to 50mg,
100 mg, 200 mg or placebo (number of patients included
not reported) [25]. This trial did not exclude patients
with known coronary artery disease, clinically significant
arrhythmia or uncontrolled hypertension. The percent-
age of patients with 2-h pain freedom was 28.6% (vs. placebo,
p= 0.003) in the 50mg group, 31.4% (vs. placebo, p < 0.001)
in the 100mg group, 38.8% (vs. placebo, p < 0.001) in the
200mg group and 21.3% in placebo group. Percentage of pa-
tients with freedom from most bothersome symptom at 2-h
was 40.8% (vs. placebo, p= 0.009) in the 50mg group, 44.2%
(vs. placebo, p < 0.001) in the 100mg group, 48.7% (vs. pla-
cebo, p < 0.001) in the 200mg group and 33.5% in the
placebo group. Adverse events included dizziness,
paresthesia, somnolence, fatigue, nausea and lethargy.
The open-label trial GLADIATOR included patients
from the prior SAMURAI and SPARTAN trials [26]. Pa-
tients were randomized to receive 100 mg or 200 mg to
treat up to eight attacks per month (number of patients
included not reported, expected a total of 2580). The pri-
mary goal was to evaluate the proportion of patients and
attacks associated with any adverse events and specific ad-
verse events. Adverse events occurred in 19% in the 100mg
group and 20% in the 200mg group. The most common
adverse events included dizziness and paresthesia.
Collectively, randomized controlled trials (RCTs) sup-
port the use of lasmiditan for the acute treatment of
migraine. The percentage of patients with 2-h pain free-
dom in trials ranges from 28.2–38.8% (Fig. 1). Further-
more, the therapeutic gain (the placebo-subtracted
response) for lasmiditan 200 mg is 16.9–17.5% which
seems similar to sumatriptan of 16–21% for doses 50–
100 mg (Fig. 2) [28]. Approximately 20% of patients re-
port adverse events most commonly dizziness and
paresthesia after intake of lasmiditan 100–200 mg [26].
Overall, the results of these trials demonstrate that las-
miditan is efficacious and well tolerated in patients with
a high level of cardiovascular risk factors. In the future,
lasmiditan will likely be approved as second-line treat-
ment if patients failed with triptans or first line
anti-migraine treatment in patients with cardiovascular
risk (or documented cardiovascular disease). Lasmiditan
is expected to be approved by the U.S. Food and Drugs
Administration (FDA) in 2019.
CGRP receptor antagonists (gepants)
Small molecule CGRP receptor antagonists are a novel
drug class called gepants (Table 2, Fig. 3). In 2004, the
first proof of concept study reported that olcegepant had
a clinical effect in humans, but this compound was never
commercialized as it cannot be orally administrated [29].
Seven gepants have been developed for the treatment of
migraine, but some of the drug development programs
have since been terminated [30]. While telcagepant dem-
onstrated a clinical effect, development ceased due to a
hepatotoxicity risk [30]. This is believed to be due to a
liver toxic metabolite that is not formed by other
gepants [31]. Currently, two gepants are in phase III
clinical trials for the acute treatment of migraine: rime-
gepant and ubrogepant (Table 2).
Rimegepant is a CGRP receptor antagonist [32] that is
administrated orally with a 75 mg dose and it has a tmax
of two hours [33]. Preliminary data from two phase III
clinical trials have been reported in press releases but
not yet published in peer-reviewed journals [34, 35].
Rimegepant was administrated as a 75mg oral dose in
the two trials (Fig. 4). Preliminary results show that
19.2% (vs. placebo, p < 0.003) of 543 patients and 19.6%
(vs. placebo, p < 0.001) of 537 patients achieve 2-h pain
Table 1 Overview of ditans in alphabetical order
Drug Status
Alniditan Development terminated
Lasmiditan (COL-144) Phase III clinical trials
LY-334370 Development terminated
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freedom compared to 14.2% of 541 patients and 12% of 535
patients with placebo, respectively [34]. Interestingly, the per-
centage of patients achieving pain freedom is reported to in-
crease over time with 66% achieving pain freedom at 8 h
compared to 47% in placebo group [35]. Freedom from most
bothersome symptom was 36.6% (vs. placebo, p < 0.002) and
37.6% (vs. placebo, p < 0.0001) in the two trials compared to
27.7% and 25.2% with placebo, respectively. Rimegepant had
no effect on hepatic function. The number of patients with
adverse events has not been reported from either trial but
the most common adverse events were nausea (1.4% in ac-
tive vs. 1.1% in placebo group) and urinary tract infections
Fig. 1 Overview of patients (%) achieving 2-h pain freedom in lasmiditan phase III clinical trials with different doses. A darker bar indicates a
higher dose. *vs. placebo, p < 0.001
Fig. 2 Overview of the therapeutic gain* in 2-h pain freedom with lasmiditan. A darker bar indicates a higher dose. *Therapeutic gain is defined
as the difference between percentage of responders in active group compared to percentage of responders in placebo group
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(1% in active vs. 0.7% in placebo group). Overall adverse
event rate is reported to be similar to placebo.
Ubrogepant is a CGRP receptor antagonist that is admin-
istrated orally with 25–100mg doses and it has a tmax of
0.7–1.5 h [36]. Preliminary data from two phase III clinical
trials (ACHIEVE I and ACHIEVE II) have been reported in
press releases but not yet published in peer-reviewed jour-
nals [37, 38]. In ACHIEVE I, 1327 patients were randomized
1:1:1 to ubrogepant 50mg, ubrogepant 100mg or placebo
(Fig. 5) [37]. The percentage of patients with 2-h pain free-
dom was 19.2% (vs. placebo, p= 0.0023) in the 50mg group,
21.2% (vs. placebo, p= 0.0003) in the 100mg group and
11.8% in the placebo group. Freedom from most bother-
some symptom at 2-h was 38.6% (vs. placebo, p = 0.0023)
and 37.7% (vs. placebo, p = 0.0023) compared to 27.8% for
placebo, respectively. No hepatoxicity was reported after in-
take of ubrogepant. The most common adverse events were
nausea, somnolence, and dry mouth all reported with a fre-
quency lower than 5%. In ACHIEVE II, 1686 patients were
randomized 1:1:1 to ubrogepant 25mg, ubrogepant 50mg
or placebo (Fig. 4) [38]. The percentage of patients with 2-h
pain freedom was 20.7% (vs. placebo, p = 0.0285) in
the 25 mg group, 21.8% (vs. placebo, p = 0.0129) in
the 50mg group and 14.3% in the placebo group. Freedom
from most bothersome symptom at 2-h was 34.1% (vs.
placebo, p = 0.0711) and 38.9% (vs. placebo, p = 0.0129),
respectively, compared to 27.4% for placebo with the 25
mg dose not being statistically significant compared to
placebo. There was no signal of hepatic toxicity in this
trial. The most common adverse events were nausea and
dizziness all reported with a frequency lower than 2.5%.
Collectively, RCTs demonstrated efficacy of gepants
for the acute treatment of migraine. The percentage of
patients with 2-h pain freedom ranges from 19.2–19.6%
with rimegepant and 19.2–21.8% with ubrogepant.
However, the therapeutic gain for gepants (rimegepant:
5%–7.6%; ubrogepant: 6.4%–9.4%) (Fig. 6) seems to be
low, especially compared to sumatriptan (16%–21% [28])
and lasmiditan (7.3%–17.5%) (Fig. 2). In addition, it is
lower compared to the therapeutic gain of telcagepant
(17% in doses 280–300 mg) [39] and it is unlikely due
unoptimized dosage or absorption rate [40]. Previous
trials of gepants caused concerns regarding the hep-
atic safety, but single treatments with rimegepant and
ubrogepant were not associated with hepatotoxicity.
Since gepants do not constrict cranial arteries [41–
43], they, like ditans, can be used as first line anti-
migraine treatment in patients with cardiovascular
Fig. 3 Overview of the therapeutic novelties targeting the calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating
polypeptide/pituitary adenylate cyclase 1 (PACAP/PAC1) pathways developed for migraine
Table 2 Overview of gepants for the treatment of migraine in alphabetical order
Drug Status
Atogepant (AGN-241689, MK-8031) Phase III clinical trials (prophylactic treatment)
BI 44370 Development terminated
MK-3207 Development terminated
Olcegepant (BIBN4096BS) Development terminated
Rimegepant (BMS-927711, BHV3000) Phase III clinical trials (acute treatment); phase II clinical trials (prophylactic treatment)
Telcagepant (MK-0974) Development terminated
Ubrogepant (MK-1602) Phase III clinical trials (acute treatment)
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Fig. 4 Overview of patients (%) achieving 2-h pain freedom in rimegepant phase III clinical trials. *Study 301; vs. placebo, p < 0.003. Study 302; vs.
placebo, p < 0.001
Fig. 5 Overview of patients (%) achieving 2-h pain freedom in ubrogepant phase III clinical trials. *ACHIEVE I; 50 mg vs. placebo, p = 0.0023;
100 mg vs. placebo, p = 0.0003. ACHIEVE II; 25 mg vs. placebo, p = 0.0285; 50 mg vs. placebo, p = 0.0129
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risk (or documented cardiovascular disease) or as
second-line treatment if patients failed with triptans.
The first gepants are expected to be approved by the
FDA in 2019/2020 [44, 45].
Novel prophylactic treatment targets
Gepants
Rimegepant (NCT03732638; phase II/III) and atogepant
(NCT02848326, NCT03700320; phase II/III, phase III)
are currently undergoing clinical trials in humans for
prophylactic treatment of migraine but only data on ato-
gepant has been released [46].
Preliminary data from the phase II clinical trial on ato-
gepant have been reported in press releases [46]. The
trial included 834 patients and was designed as a
placebo-controlled dose ranging study with doses ran-
ging from atogepant 10 mg once a day to 60 mg twice a
day. All doses showed a significant reduction in mean
monthly migraine days compared to placebo. The trial
raised no concerns regarding hepatic or cardiovascular
safety. Efficacy and safety data on atogepant need to be
confirmed in phase III clinical trials.
Anti-CGRP mAbs
To date, four mAbs targeting the CGRP pathway have
been developed (Table 3) and three of them have already
been approved for the preventive treatment of migraine
[47–49]. In the following we review data derived from
recent phase III trials.
Erenumab is a humanized IgG2 mAb that targets the
CGRP receptor [50, 51] and administered as monthly
subcutaneous injections of either 70 mg or 140 mg. The
mean tmax is 5.5 days and the plasma half-time is ap-
proximately 21–23 days [52]. The Tmax corresponds with
an early onset of effect with separation from placebo
within the first week of treatment [53]. It has recently
been approved for therapeutic use for the preventive
treatment of migraine [47]. Data from two phase III clin-
ical trials (ARISE and STRIVE) are presented in the fol-
lowing (Fig. 7). In ARISE, 577 patients were randomized
Table 3 Overview of anti-calcitonin-gene related (CGRP) (receptor) peptide monoclonal antibodies in order by target and
alphabetical
Drug Target Administration Interval between administrations Status
Erenumab (AMG-334) Receptor Subcutaneous injection 4 weeks FDA approved; phase III clinical trials
Eptinezumab (ALD403) Ligand Intravenous infusion 12 weeks Phase III clinical trials
Fremanezumab (TEV-48125) Ligand Subcutaneous injection 4 or 12 weeks FDA approved; phase III clinical trials
Galcanezumab (LY2951742) Ligand Subcutaneous injection 4 weeks FDA approved; phase III clinical trials
*FDA: The US Food and Drug Administration
Fig. 6 Overview of the therapeutic gain* in 2-h pain freedom with gepants. A darker bar indicates a higher dose. *Therapeutic gain is defined as
the difference between percentage of responders in active group compared to percentage of responders in placebo group
Do et al. The Journal of Headache and Pain           (2019) 20:37 Page 6 of 13
to monthly injections of 70 mg erenumab or placebo
[54]. The percentage of patients achieving a > 50% reduc-
tion in monthly migraine days was 39.7% (p = 0.010) in
the active group and 29.5% in the placebo group. Ad-
verse event rates were similar between erenumab and
placebo. In STRIVE, 955 patients were randomized to
monthly injections of erenumab 70 mg, 140 mg or pla-
cebo [55]. The percentage of patients achieving > 50%
reduction in monthly migraine days was 43.3% (vs. pla-
cebo, p < 0.001) with 70mg, 50.0% (vs. placebo, p <
0.001) with 140 mg and 26.6% with placebo. There was
no difference in adverse events between erenumab and
placebo. The trial reported 8.0% of the 70 mg group and
3.2% of the 140 mg group creating anti-erenumab bind-
ing antibodies, however, only 5.6% of the patients were
available for analysis.
Eptinezumab is a humanized IgG1 mAb that binds to both
α and β forms of the human CGRP ligand [56]. The drug is
administrated with intravenous infusions every 12weeks.
The plasma half-time of the drug is 31 days [56]. There is
one completed phase III clinical trial (PROMISE I) [57], one
ongoing phase III clinical trial (PROMISE II, NCT02974153)
[58] and one ongoing safety open-label study (PREVAIL,
NCT02985398) [59, 60]. Preliminary data from the PROM-
ISE I [61, 62] and PROMISE II [63] trials (Fig. 8) have been
reported in press releases but not yet published in
peer-reviewed journals. In PROMISE I, 888 patients were
randomized to receive eptinezumab 30mg, 100mg, 300mg
or placebo infusions once every 12weeks [61, 62]. For week
1–12, percentage of patients achieving > 50% reduction in
monthly migraine days was 49.8% (vs. placebo, p= 0.0085)
with 100mg, 56.3% (vs. placebo, p= 0.0001) with 300mg
and 37.4% with placebo [61]. For month 6–12, 70.7% pa-
tients had a > 50% reduction in monthly migraine days com-
pared to 58.7% for placebo [62]. Differences between doses
were not reported for month 6–12. The most commonly re-
ported adverse events across all eptinezumab groups were
upper respiratory infection (10.5%), nasopharyngitis (6.8%),
and sinusitis (3.6%). In PROMISE II, 1072 patients were ran-
domized to eptinezumab 100mg, 300mg or placebo [63].
The percentage of patients achieving > 50% reduction in
monthly migraine days at week 1–12 were 58% (vs. placebo,
p < 0.0001) with 100mg, 61% (vs. placebo, p < 0.0001) in 300
mg and 39% with placebo. The incidence of adverse events
was not statistically different from the placebo group.
Fremanezumab is a humanized IgG2 mAb that binds
to both α and β forms of the human CGRP ligand [64].
Fremanezumab has recently been approved for thera-
peutic use for the preventive treatment of migraine [48].
The drug is administered as subcutaneous injections
with either monthly low-dose 225 mg injections or quar-
terly high-dose 675 mg injections. The tmax is 5–7 days
and the plasma half-time of the drug is 31 days. The tmax
corresponds with an early onset of effect with separation
from placebo within the first week of treatment [65]. Re-
sults from two phase III clinical trials have been pub-
lished in peer-reviewed journals (Fig. 9). In a phase III
clinical trial [66], 1130 chronic migraine patients were
randomized 1:1:1 to monthly low-dose 225 mg injec-
tions, quarterly high-dose 675 mg injections or placebo.
Percentage of patients with > 50% reduction in monthly
migraine days was 41% (vs. placebo, p < 0.001) in
monthly group, 38% (vs. placebo, p < 0.001) in quarterly
group and 18% in the placebo group. Most common
Fig. 7 Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with erenumab. A darker bar indicates a
higher dose. *ARISE; 70 mg vs. placebo, p = 0.010. STRIVE; 70 mg vs. placebo, p < 0.001; 140 mg vs. placebo, p < 0.001
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adverse event was injection site pain. Two (0.5%) pa-
tients in the high-dose quarterly group developed
anti-drug antibodies. Similar results were reported in an-
other phase III clinical trial with 875 episodic migraine
patients randomized to monthly low-dose 225 mg
injections or quarterly high-dose 675 mg injections [67].
Percentage of patients with > 50% migraine frequency
reduction was 47.7% (vs. placebo, p < 0.001) in monthly
group, in 44.4% (vs. placebo, p < 0.001) quarterly group,
and 27.9% in placebo group. Four patients (1.4%) in the
Fig. 9 Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with fremanezumab. A darker bar indicates a
higher dose. *NCT02629861 (left); 225 mg vs. placebo, p < 0.001; 675 mg vs. placebo, p < 0.001. NCT02629861 (right); 225 mg vs. placebo, p < 0.001;
675 mg vs. placebo, p < 0.001
Fig. 8 Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with eptinezumab. A darker bar indicates a
higher dose. *PROMISE I; 100 mg vs. placebo, p = 0.0085; 300 mg vs. placebo, p = 0.0001. PROMISE II; 100 mg vs. placebo, p < 0.0001; 300 mg vs.
placebo, p < 0.0001
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low-dose monthly group developed anti-drug antibodies.
The most common adverse events were also injection
site reactions. In addition, post-hoc analyses show that
fremanezumab is safe and effective as add-on treatment
for migraine patients who is already on stable doses of
other preventive migraine medication [68].
Galcanezumab is a humanized IgG4 mAb that binds to
both α and β forms of the human CGRP ligand. Galca-
nezumab has recently been approved for the preventive
treatment of migraine [49]. The drug is administered as
monthly subcutaneous injections. The tmax is 7–13 days
and the plasma half-time of the drug is 28 days. Results
from two phase III clinical trials (EVOLVE-1 and
EVOLVE-2) have been published in peer-reviewed jour-
nals (Fig. 10). In EVOLVE-1, 1671 patients were ran-
domized 1:1:2 to galcanezumab 120 mg, 240 mg or
placebo [69]. Percentage of patients with > 50% migraine
frequency reduction was 60.9% (vs. placebo, p < 0.001) in
240 mg group, 62.3% (vs. placebo, p < 0.001) in 120mg
group and 38.6% in placebo group. The most common
adverse event was injection site reactions. The number
of treatment related adverse events was not statistically
significant between the active and placebo groups. The
percentage of patients who had anti-drug antibodies
present after treatment were 5.2% in 240mg group, 3.5%
in 120 mg group and 1.7% in placebo group. In
EVOLVE-2, 915 patients were randomized 1:1:2 to galca-
nezumab 120 mg, 240 mg or placebo [70]. Percentage of
patients with > 50% migraine frequency reduction was
59% (vs. placebo, p < 0.001) in 240 mg group, 57% (vs.
placebo, p < 0.001) in 120 mg group and 36% in placebo
group. The most common adverse event was injection
site reactions with a higher rate in the active groups
compared to placebo. There was no difference in num-
ber of serious adverse events between the groups. The
percentage of patients who had anti-drug antibodies
present after treatment was 5.1% in 240 mg group, 8.6%
in 120 mg group and 0.5% in placebo group.
Treatment-emergent anti-drug antibodies had no impact
on either safety or efficacy.
The introduction of anti-CGRP mAbs is a great ad-
vancement in migraine treatment because of responder
rates with very favorable adverse event profiles. The
highest percentage of patients with > 50% reduction in
migraine days with each mAb ranges from 47.7%–62%.
This suggests a difference in the ratio of responders be-
tween the different mAbs. However, the therapeutic gain
range is 22–23.7% indicating that anti-CGRP mAbs have
a similar efficacy regardless of target (receptor or ligand)
and administration form (subcutaneous or intravenous)
(Fig. 11). The therapeutic gain with erenumab is in-
creased with higher dosage (Fig. 11). Interestingly, the
proportion of patients reaching ≥75% reduction from
baseline at 3 months is also statistically significant with
anti-CGRP mAbs compared to placebo. This suggests
that there are subpopulations who greatly benefit from
anti-CGRP mAbs. Efforts should be made to identify
these patients and biomarkers that can predict treatment
Fig. 10 Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with galcanezumab. A darker bar indicates
a higher dose. *EVOLVE-1; 120 mg vs. placebo, p < 0.001; 240 mg vs. placebo, p < 0.001. EVOLVE-2; 120 mg vs. placebo, p < 0.001; 240 mg vs.
placebo, p < 0.001
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response. The long-term effects (sustained efficacy and
safety) of anti-CGRP mAbs remains to be investigated
in real world studies. The rate of anti-drug binding
antibodies is low in all trials reporting this parameter
[55, 66, 67, 69, 70]. Adverse events related to the devel-
opment of anti-drug antibodies has not been reported
in anti-CGRP clinical trials. Whether anti-drug anti-
bodies inactivate the clinical effect depends on the con-
centration of neutralizing anti-drug antibodies.
Consequently, the detection of anti-drug antibodies it-
self is not a contraindication for treating with anti-
CGRP mAbs.
Anti-pituitary adenylate cyclase-activating polypeptide mAbs
Pituitary adenylate cyclase-activating polypeptide
(PACAP) belongs to the superfamily of glucagon/secre-
tin peptides and two bioactive forms exist, PACAP38
and PACAP27 [71]. PACAP38 exists in the trigemino-
vascular system and deep brain structures amongst
others [72–75]. PACAP38 mediates its effect through
three receptors, pituitary adenylate cyclase-activating
polypeptide type I (PAC1), VPAC1 and VPAC2. Like the
CGRP pathway, these receptors cause an activation of
adenylate cyclase leading to increased cAMP production
[76]. Vasoactive intestinal peptide (VIP) has a similar
structure to PACAP38 and affinity for VPAC1 and
VPAC2 receptors. The two peptides differs in that
PACAP38 has a much higher affinity for the PAC1 re-
ceptor [77]. Furthermore, PACAP38 infusions can
cause migraine-like attacks while VIP cannot [78, 79].
Thus, only PACAP38 and the PAC1 receptor in this
pathway are of interest as drug targets.
There are currently two mAbs, ALD1910 and
AMG-301, in development for the PACAP38 pathway
(Fig. 3) (Table 4). ALD1910 targets the PACAP38 ligand
[80] and AMD-301 targets the PAC1 receptor [81].
ALD1910 is undergoing preclinical studies and AMG-301
has recently undergone a phase II clinical trial
(NCT03238781). No results of either drug have been re-
leased so far but results from the AMG-301 trial is ex-
pected to be published mid-2019.
Concluding remarks
The development of ditans, gepants and anti-CGRP
mAbs for the treatment of migraine is one of the great-
est advances in the migraine field. Lasmiditan, rimege-
pant and ubrogepant will extend our therapeutic
armamentarium for managing acute migraine attacks
when triptans are not effective or contraindicated due to
cardiovascular disorders. The mAbs against CGRP and
its receptor have high responder rates with favorable ad-
verse event profiles. Furthermore, the mAbs also offer
convenient treatment regimens of 4- or 12-week inter-
vals. These factors will contribute to a better adherence.
Fig. 11 Overview of the therapeutic gain* in percentage of patients with > 50% reduction in migraine days with anti-calcitonin gene-related
peptide monoclonal antibodies. A darker bar indicates a higher dose. *Therapeutic gain is defined as the difference between percentage of
patients in active group compared to percentage of patients in placebo group
Table 4 Overview of anti-pituitary adenylate cyclase-activating polypeptide/pituitaryadenylate cyclase 1 (PACAP/PAC1)
monoclonal antibodies
Drug Target Administration Interval between administrations Status
ALD1910 Ligand N/A N/A Preclinical phase
AMG-301 Receptor Subcutaneous injection 4 weeks Phase II clinical trials
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Given that approximately 40–50% of migraine patients
do not respond to mAbs, future studies should focus on
identification of biomarkers that can predict treatment
response. Collectively, novel migraine therapies repre-
sent a major progress in migraine treatment and will
undoubtedly transform headache medicine.
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